NewAmsterdam Pharma Company NV
NAMS
View Detailed Chart
37.400USD
+0.400+1.08%
Market hours （ET）Quotes delayed by 15 min
4.21BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.08%
5 Days
+3.77%
1 Month
+21.94%
6 Months
+86.72%
Year to Date
+45.53%
1 Year
+109.88%
View Detailed Chart
TradingKey Stock Score of NewAmsterdam Pharma Company NV
Currency: USD Updated: 2025-11-03Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NewAmsterdam Pharma Company NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
15
analysts
Buy
Current Rating
43.000
Target Price
+13.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NewAmsterdam Pharma Company NV Highlights
StrengthsRisks
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.56M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 45.56M.
Undervalued
The company’s latest PE is -23.18, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 119.62M shares, increasing 2.53% quarter-over-quarter.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 832.17K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
NewAmsterdam Pharma Company NV Info
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Ticker SymbolNAMS
CompanyNewAmsterdam Pharma Company NV
CEODr. Michael Harvey Davidson, M.D.
Websitehttps://ir.newamsterdampharma.com/
Related Instruments
+1.98%
-0.35%
+0.39%
-5.18%
+1.20%
-0.29%
+0.11%
-1.01%
+5.42%
-3.21%
-1.22%
+0.22%
+0.15%
+0.17%
+0.59%
+10.51%
-0.28%
+1.70%
-0.59%
-0.15%Popular Symbols
